The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma
Abstract Glioblastoma is the most common malignant primary brain tumor. To date, clinically relevant biomarkers are restricted to isocitrate dehydrogenase (IDH) gene 1 or 2 mutations and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Long non-coding RNAs (lncRNAs) have been show...
Main Authors: | Ulvi Ahmadov, Daniel Picard, Jasmin Bartl, Manuela Silginer, Marija Trajkovic-Arsic, Nan Qin, Lena Blümel, Marietta Wolter, Jonathan K. M. Lim, David Pauck, Alina Marie Winkelkotte, Marlen Melcher, Maike Langini, Viktoria Marquardt, Felix Sander, Anja Stefanski, Sascha Steltgens, Christina Hassiepen, Anna Kaufhold, Frauke-Dorothee Meyer, Annette Seibt, Lara Kleinesudeik, Anika Hain, Carsten Münk, Christiane Brigitte Knobbe-Thomsen, Alexander Schramm, Ute Fischer, Gabriel Leprivier, Kai Stühler, Simone Fulda, Jens T. Siveke, Felix Distelmaier, Arndt Borkhardt, Michael Weller, Patrick Roth, Guido Reifenberger, Marc Remke |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-021-04146-0 |
Similar Items
-
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
by: Arndt Borkhardt, et al.
Published: (2023-01-01) -
Regulatory effects and mechanisms of HOTAIRM1 in malignant tumors
by: ZHAO Yu-qiao, SU Zhi-lei, CUI Yun-fu, GUAN Cang-hai, JIANG Xing-ming
Published: (2021-02-01) -
Primary cilia contribute to the aggressiveness of atypical teratoid/rhabdoid tumors
by: Lena Blümel, et al.
Published: (2022-09-01) -
Targeting HOTAIRM1 ameliorates glioblastoma by disrupting mitochondrial oxidative phosphorylation and serine metabolism
by: Wei Han, et al.
Published: (2022-08-01) -
Identification and Validation of HOTAIRM1 as a Novel Biomarker for Oral Squamous Cell Carcinoma
by: Yixiu Yu, et al.
Published: (2022-01-01)